

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammato⦠read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
$37.38
Price-5.20%
-$2.05
$2.770b
Mid
747.6x
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$529.332m
-
1y CAGR-
3y CAGR-
5y CAGR$4.790m
-
1y CAGR-
3y CAGR-
5y CAGR$0.04
-
1y CAGR-
3y CAGR-
5y CAGR$495.007m
$661.150m
Assets$166.143m
Liabilities$9.765m
Debt1.5%
1.7x
Debt to EBITDA$66.491m
-
1y CAGR-
3y CAGR-
5y CAGR